SOLICITATION NOTICE
65 -- Vaccine for Antrhax
- Notice Date
- 8/28/2006
- Notice Type
- Solicitation Notice
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W 6707 Democracy Blvd., MSC 5455, Bethesda, MD, 20892-5455
- ZIP Code
- 20892-5455
- Solicitation Number
- NIH-NIDDK-06-1001
- Response Due
- 9/21/2006
- Archive Date
- 10/6/2006
- Description
- The National Institutes of health (NIH), The National Institute of Child Health and Human Development (NICHD), the Laboratory of Developmental and Molecular Immunity (LDMI) has developed a unique vaccine for anthrax. This improved vaccine is a purified recombinant protective antigen of Bacillus antracis. This research is dedicated to bioterrorism. Testing of this new vaccine is crucial to determine its effectiveness. NICHD intends to procure the services of Georgetown University Medical School, 3800 Reservoir Road 2 PHC, Washington, DC 20007. The contractor shall provide the following services: Recruit interview potential volunteers and have their blood analyzed for hepatitis B and C and liver functions. Female volunteers will also be tested for pregnancy. The Contractor shall choose 50 volunteers, based upon the interview and test results. The volunteers will be injected with one of 7 vaccine formulations according to random numbers provided. The subjects will be monitored for local reaction, fever and systemic reactions at 30 minutes and 72 hours. Diary cards will be collected on day 1, 2, and 4 through 7. The Contractor will examine the volunteers with severe reactions or upon their request, during that time. Blood samples will be taken for liver functions on day 7. The 2nd and 3rd injections (2 and 4 months after the first) will follow the same procedure; blood will be taken before each injection for PA antibodies and pregnancy test from female volunteers. The 4th injection will be given at 16 months with a blood sample for PA antibodies taken before and 2 weeks after the 4th injection. The last serum sample will be taken 1 year later (at 28 months). Between the 3rd and the 4th injections, the volunteers will be contacted by phone every 2 to 3 months to inquire about their health. Georgetown University is uniquely qualified and has experience in conducting clinical trials involving vaccines and has the required staffing, space and knowledge to provide this service. Interested vendors may identify, in writing, their interest with a capability statement to the Contracting Office prior to the closing date of this notice. This notice of intent is not a request for competitive proposals, however; all responses received, before the closing date, of this announcement will be considered by the Government. A determination by the Government not to compete this proposed acquisition is based upon responses to this notice and is solely within the discretion of the Government. It is anticipated that the Request for Quotation (RFQ) NIH-NIDDK-06-1001 will be available fifteen (15) days after the publication date of this synopsis. Receipt of quotations will be due ten (10) days after the release of the RFQ. The anticipated award date is September 22, 2006. Request for copies of the RFQ must be in writing to the National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 775, Bethesda, MD 20817 Attention: Patricia Haun. FAXED quotations must contain offerors name, address, telephone number and fax number. FAXED quotations will be accepted if dated and signed by an authorized company representative. FAX number 301-480-8502.
- Record
- SN01127276-W 20060830/060828220322 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |